- Home
- AVD vs RAPT Comparison
AVD vs RAPT Comparison
Compare AVD & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVD
- RAPT
- Stock Information
- Founded
- AVD 1969
- RAPT 2015
- Country
- AVD United States
- RAPT United States
- Employees
- AVD N/A
- RAPT N/A
- Industry
- AVD Agricultural Chemicals
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- AVD Industrials
- RAPT Health Care
- Exchange
- AVD Nasdaq
- RAPT Nasdaq
- Market Cap
- AVD 135.6M
- RAPT 117.5M
- IPO Year
- AVD N/A
- RAPT 2019
- Fundamental
- Price
- AVD $4.46
- RAPT $0.75
- Analyst Decision
- AVD Strong Buy
- RAPT Hold
- Analyst Count
- AVD 1
- RAPT 7
- Target Price
- AVD $14.00
- RAPT $5.00
- AVG Volume (30 Days)
- AVD 134.0K
- RAPT 829.4K
- Earning Date
- AVD 05-20-2025
- RAPT 05-08-2025
- Dividend Yield
- AVD 0.68%
- RAPT N/A
- EPS Growth
- AVD N/A
- RAPT N/A
- EPS
- AVD N/A
- RAPT N/A
- Revenue
- AVD $553,839,000.00
- RAPT N/A
- Revenue This Year
- AVD N/A
- RAPT N/A
- Revenue Next Year
- AVD $4.35
- RAPT N/A
- P/E Ratio
- AVD N/A
- RAPT N/A
- Revenue Growth
- AVD N/A
- RAPT N/A
- 52 Week Low
- AVD $3.28
- RAPT $0.75
- 52 Week High
- AVD $12.67
- RAPT $8.58
- Technical
- Relative Strength Index (RSI)
- AVD 58.33
- RAPT 33.73
- Support Level
- AVD $4.10
- RAPT $0.75
- Resistance Level
- AVD $4.33
- RAPT $0.85
- Average True Range (ATR)
- AVD 0.19
- RAPT 0.08
- MACD
- AVD 0.06
- RAPT -0.00
- Stochastic Oscillator
- AVD 91.25
- RAPT 0.97
About AVD American Vanguard Corporation ($0.10 Par Value)
American Vanguard Corp is a United States-based diversified specialty and agricultural products company. It manufactures and formulates chemicals for crops, turf and ornamental plants, and human and animal health protection. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.